South Korean biopharmaceutical Samsung Biologics bids for Swiss pharma ingredient firm Polypeptide.
Billions-on-the-table bid for Swiss pharmaceutical supplier Polypeptide
Keystone-SDA
The South Korean contract biopharmaceutical manufacturer Samsung Biologics intends to acquire the Swiss active pharmaceutical ingredient manufacturer Polypeptide.
Generated with artificial intelligence.
This content was published on
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide
Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
Offerta miliardaria per l’elvetica PolyPeptide - RSI
Samsung Biologics punta al mercato dei farmaci anti-obesità: opa da 1,8 miliardi sulla svizzera PolyPeptide
Samsung Biologics, opa da 1,8 miliardi sulla svizzera PolyPeptide: focus sui farmaci dimagranti | MilanoFinanza News
Samsung Biologics expands into peptides with $1.8b PolyPeptide deal
1.8B Deal Puts Samsung Biologics Ahead in CDMO Race
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the…
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for…
Samsung Biologics said Monday it will acquire Swiss peptide drug manufacturer PolyPeptide Group through an all-cash public tender…
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with…
Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1…
Samsung Biologics offre 1,5 miliardi di franchi per acquisire PolyPeptide, produttore svizzero di peptidi. Il CdA elvetico…
